MULTIPLE MYELOMA WITH FAILED REMISSION
Clinical trials for MULTIPLE MYELOMA WITH FAILED REMISSION explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA WITH FAILED REMISSION trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA WITH FAILED REMISSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug tested for Tough-to-Treat blood cancer
Disease control OngoingThis is an early-stage study to test the safety of a new drug called HPN217 (or MK-4002) for people with multiple myeloma that has come back or stopped responding to other treatments. Researchers will give increasing doses to about 100 participants to find the highest dose that i…
Matched conditions: MULTIPLE MYELOMA WITH FAILED REMISSION
Phase: PHASE1 • Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Can an app empower cancer patients?
Knowledge-focused OngoingThis study is testing whether using a digital health platform called All4Cure helps people with multiple myeloma feel more in control of their health. About 200 participants will fill out surveys over a year to measure their engagement and symptom burden. The goal is to see if th…
Matched conditions: MULTIPLE MYELOMA WITH FAILED REMISSION
Sponsor: All4Cure • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:43 UTC